Viela Bio Announces Proposed Public Offering of Common Stock
May 26 2020 - 7:24AM
Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology
company pioneering treatments for autoimmune and severe
inflammatory diseases, today announced that it intends to offer and
sell, subject to market and other conditions, 3,000,000 shares
of its common stock in an underwritten public offering. In
addition, certain selling stockholders expect to grant the
underwriters a 30-day option to purchase up to an additional
450,000 shares of common stock from the selling stockholders.
Morgan Stanley, Goldman Sachs & Co.
LLC, Cowen and Guggenheim Securities are acting as the
joint book-running managers for the offering.
Viela Bio intends to use the net proceeds from the offering to
support activities for the commercialization of inebilizumab for
the treatment of NMOSD, if approved; to advance the ongoing
clinical development of inebilizumab in other indications and of
VIB4920, VIB7734 and other pipeline candidates; and for working
capital and other general corporate purposes. Viela Bio will not
receive any proceeds from any sale of shares by the selling
stockholders.
The proposed offering is being made only by means of a
prospectus. Copies of the preliminary prospectus related to the
offering may be obtained, when available, from:
- Morgan Stanley & Co. LLC, Attention: Prospectus
Department, 180 Varick Street, Second Floor, New York,
NY 10014;
- Goldman Sachs & Co. LLC, Attention: Prospectus
Department, 200 West Street, New York, NY 10282,
email: prospectus-ny@ny.email.gs.com, telephone:
1-866-471-2526, fax: 1-212-902-9316;
- Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attention: Prospectus Department,
email: PostSaleManualRequests@broadridge.com, telephone:
1-833-297-2926; or
- Guggenheim Securities, LLC, Attention: Equity Syndicate
Department, 330 Madison Avenue, New York, NY 10017,
email: GSEquityProspectusDelivery@guggenheimpartners.com,
telephone: 1-212-518-5548.
A registration statement relating to these securities was filed
with the Securities and Exchange Commission on May 26,
2020 but has not yet become effective. These securities may not be
sold, nor may offers to buy be accepted, prior to the time the
registration statement becomes effective. This press release shall
not constitute an offer to sell or a solicitation of an offer to
buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Viela BioViela Bio, headquartered in
Gaithersburg, Maryland, is a clinical-stage biotechnology company
pioneering treatments for autoimmune and severe inflammatory
diseases.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, contained in this press
release, including statements regarding the completion, timing and
size of the proposed public offering and use of proceeds therefrom,
are forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue” or the negative of these terms or
other comparable terminology, which are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. We may not actually
achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements we make. Various
factors may cause differences between our expectations and actual
results as discussed in greater detail in our filings with
the Securities and Exchange Commission (SEC), including
without limitation, risks and uncertainties related to global
economic or market conditions, volatility in the share price of our
common stock, changes in our operating plans or funding
requirements and the risks and uncertainties described in the
section entitled “Risk Factors” in our annual report on Form 10-K
for the year ended December 31, 2019 that was filed with
the SEC on March 25, 2020 and our subsequent
periodic and current reports filed with the SEC. We do not assume
any obligation to update any forward-looking statements, whether as
a result of new information, future events or otherwise, except as
required by law.
Source: Viela Bio
Contacts:
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Amy Bonanno
914-450-0349
abonanno@soleburytrout.com
Viela Bio (NASDAQ:VIE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Viela Bio (NASDAQ:VIE)
Historical Stock Chart
From Apr 2023 to Apr 2024